Verastem Executive Sale and Clinical Trial Updates
Verastem, Inc. (NASDAQ:VSTM) reported a recent stock sale by its Chief Financial Officer, Daniel Calkins, alongside positive updates from its clinical development pipeline. While Calkins disposed of 4,089 shares to cover withholding obligations tied to restricted stock unit vesting, the company continues to advance its oncology programs. The stock …